Categories AlphaGraphs, Earnings, Health Care
Vertex Pharmaceuticals (VRTX) Earnings: 4Q22 Key Numbers
Vertex Pharmaceuticals Incorporated (NASDAQ: VRTX) reported total revenues of $2.3 billion for the fourth quarter of 2022. This compares to $2 billion in the same period a year ago.
GAAP net income rose 6% year-over-year to $819 million, or $3.15 per share. Adjusted EPS increased 25% to $3.76.
For full-year 2023, CF product revenues are expected to be $9.55-9.70 billion.
Looking for more insights on the earnings results? Click here to access the full transcripts of the latest earnings conference calls!
Most Popular
United Parcel Service (UPS) seems on track to regain lost strength
Cargo giant United Parcel Service, Inc. (NYSE: UPS) ended fiscal 2023 on a weak note, reporting lower revenues and profit for the fourth quarter. The company experienced a slowdown post-pandemic
IPO Alert: What to look for when Boundless Bio goes public
Boundless Bio is preparing to debut on the Nasdaq stock market this week, and become the latest addition to the list of biotech firms that have launched IPOs this year.
Nike (NKE) bets on innovation and partnerships to return to high growth
Sneaker giant Nike, Inc. (NYSE: NKE) has been going through a rough patch for some time, with sales coming under pressure from weak demand and rising competition. Post-pandemic, the company